Palvella Therapeutics Inc

Research Palvella Therapeutics Inc (PVLA) on Bullrun: market cap USD 2.22B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerPVLA
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 2.22B
• Financial periodFY2025
• Net income-USD 41.72M

Valuation Snapshot

latest market cap is USD 2.22B.

About Palvella Therapeutics Inc

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.

Frequently asked questions

What is Palvella Therapeutics Inc's market cap?

Palvella Therapeutics Inc's market capitalization is USD 2.22B.

What does Palvella Therapeutics Inc do?

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.